EA201401134A1 - Hla-рестиктированные пептидоспецифические антигенсвязывающие белки - Google Patents

Hla-рестиктированные пептидоспецифические антигенсвязывающие белки

Info

Publication number
EA201401134A1
EA201401134A1 EA201401134A EA201401134A EA201401134A1 EA 201401134 A1 EA201401134 A1 EA 201401134A1 EA 201401134 A EA201401134 A EA 201401134A EA 201401134 A EA201401134 A EA 201401134A EA 201401134 A1 EA201401134 A1 EA 201401134A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
binding proteins
antigen binding
hla
fragments
Prior art date
Application number
EA201401134A
Other languages
English (en)
Inventor
Най-Конг Чеунг
Димитер Тассев
Цзянь Ху
Original Assignee
Мемориал Слоан-Кеттеринг Кэнсер Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемориал Слоан-Кеттеринг Кэнсер Сентер filed Critical Мемориал Слоан-Кеттеринг Кэнсер Сентер
Publication of EA201401134A1 publication Critical patent/EA201401134A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описаны антигенсвязывающие белки с TCR-подобными паратопами, т.е. с антигенсвязывающей областью, специфичной к HLA-A2-рестриктированному пептиду. Антигенсвязывающие белки включают антитела в различных формах, включая полноразмерные антитела, в основном интактные антитела, Fab-фрагменты, F(ab')-фрагменты и одноцепочечные Fv-фрагменты. В изобретении также рассматриваются гибридные белки, такие как гибриды scFv с иммуноглобулином или с Т-клеточными рецепторными доменами, включающими антигенсвязывающую область, специфичную к каждому пептиду. Кроме того, в изобретении также рассматриваются иммуноконъюгаты, которые могут включать антитела, связанные с радиоизотопом, флуоресцентным маркером или другим детектируемым маркером, с цитотоксином или другой молекулой. Кроме того, иммуноконъюгат может быть использован для доставки агента, необходимого для вырабатывания терапевтического эффекта или для улучшения иммунной эффекторной функции.
EA201401134A 2011-02-11 2012-02-13 Hla-рестиктированные пептидоспецифические антигенсвязывающие белки EA201401134A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161463082P 2011-02-11 2011-02-11

Publications (1)

Publication Number Publication Date
EA201401134A1 true EA201401134A1 (ru) 2015-05-29

Family

ID=45755563

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201401134A EA201401134A1 (ru) 2011-02-11 2012-02-13 Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
EA201391159A EA201391159A1 (ru) 2011-02-11 2012-02-13 Hla-рестриктированные пептидоспецифические антигенсвязывающие белки

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201391159A EA201391159A1 (ru) 2011-02-11 2012-02-13 Hla-рестриктированные пептидоспецифические антигенсвязывающие белки

Country Status (11)

Country Link
US (3) US9040669B2 (ru)
EP (2) EP2673300B1 (ru)
KR (1) KR101944557B1 (ru)
CN (1) CN103635486B (ru)
AU (1) AU2012214132B2 (ru)
CA (1) CA2826942C (ru)
EA (2) EA201401134A1 (ru)
HK (1) HK1223942A1 (ru)
SG (2) SG10201602159VA (ru)
WO (1) WO2012109659A1 (ru)
ZA (1) ZA201306646B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
AU2014246658B2 (en) * 2013-04-03 2018-10-04 Peter Maccallum Cancer Institute Antibodies against human RYK and uses therefor
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
EP3250606B1 (en) 2015-01-26 2020-11-25 Cellectis Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy
CN108137685B (zh) * 2015-03-23 2022-11-11 约翰·霍普金斯大学 由体细胞突变基因编码的hla限制性表位
CN114478791A (zh) 2015-04-03 2022-05-13 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3307319A4 (en) 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center ANTIBODIES SPECIFIC TO T-CELL RECEPTORS SPECIFIC TO EBV LATENT 2A MEMBRANE PROTEIN PRESENTED BY HUMAN HLA
WO2018005775A1 (en) 2016-06-29 2018-01-04 Memorial Sloan-Kettering Cancer Center Cd47 blockade enhances therapeutic activity of antibodies to low density cancer epitopes
EP3568468A4 (en) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
EP3630846A4 (en) * 2017-05-31 2021-02-24 Carsgen Therapeutics Co., Ltd. COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY
AU2017418590A1 (en) 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
CA3066779A1 (en) 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
JP2020530277A (ja) 2017-06-30 2020-10-22 セレクティスＣｅｌｌｅｃｔｉｓ 反復投与のための細胞免疫療法
PL3428194T3 (pl) 2017-07-14 2022-01-17 Immatics Biotechnologies Gmbh Ulepszona cząsteczka polipeptydu o podwójnej specyficzności
EP3684408A1 (en) 2017-09-19 2020-07-29 Massachusetts Institute of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
MA51302A (fr) * 2017-12-21 2021-03-31 Hoffmann La Roche Anticorps se liant à hla-a2/wt1
CN111247429A (zh) * 2017-12-21 2020-06-05 豪夫迈·罗氏有限公司 用于新颖抗原结合模块的特异性测试的通用报告细胞测定法
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
EP3775883A1 (en) * 2018-04-04 2021-02-17 F. Hoffmann-La Roche AG Diagnostic assays to detect tumor antigens in cancer patients
CN108752473B (zh) * 2018-05-03 2021-08-31 陕西师范大学 一种抗c5全人源单链抗体c5b3及其应用
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
CN109293774B (zh) * 2018-10-16 2021-05-28 南京医科大学 特异性结合cd19的全人源化抗体及应用
CN110358793A (zh) * 2019-05-30 2019-10-22 南京艾德免疫治疗研究院有限公司 一种用于car-t制备的慢病毒载体制备方法
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
AU2021236145A1 (en) 2020-03-10 2022-09-22 Dana-Farber Cancer Institute, Inc. Methods for generating engineered memory-like NK cells and compositions thereof
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
CN113278068B (zh) * 2020-06-04 2023-11-10 山东宽和正生物医药有限公司 针对新冠病毒SARS-CoV-2的单克隆抗体F5
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023122574A1 (en) * 2021-12-20 2023-06-29 The Children's Hospital Of Philadelphia Chimeric antigen receptor (car) vectors and libraries and methods of high throughput car screening
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023164607A2 (en) * 2022-02-25 2023-08-31 Trustees Of Dartmouth College Afucosylation of hla-specific igg1 as a potential predictor of antibody pathogenicity in kidney transplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU2003220079A1 (en) * 2002-03-08 2003-09-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
US20100158927A1 (en) * 2007-03-29 2010-06-24 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
TWI504407B (zh) * 2007-12-05 2015-10-21 Int Inst Cancer Immunology Inc 癌疫苗組合物
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2010106431A2 (en) * 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof

Also Published As

Publication number Publication date
NZ615257A (en) 2015-07-31
KR20140014165A (ko) 2014-02-05
SG10201602159VA (en) 2016-04-28
AU2012214132B2 (en) 2016-07-28
US20150322154A1 (en) 2015-11-12
US20140296492A1 (en) 2014-10-02
ZA201306646B (en) 2014-11-26
WO2012109659A1 (en) 2012-08-16
US9040669B2 (en) 2015-05-26
EP3006467A1 (en) 2016-04-13
NZ702372A (en) 2016-06-24
HK1223942A1 (zh) 2017-08-11
AU2012214132A1 (en) 2013-09-05
CA2826942C (en) 2021-08-03
CA2826942A1 (en) 2012-08-16
EP2673300A1 (en) 2013-12-18
KR101944557B1 (ko) 2019-01-30
SG193023A1 (en) 2013-10-30
CN103635486A (zh) 2014-03-12
US20140024809A1 (en) 2014-01-23
CN103635486B (zh) 2017-05-17
EP2673300B1 (en) 2016-08-24
EA201391159A1 (ru) 2014-02-28
US9453075B2 (en) 2016-09-27

Similar Documents

Publication Publication Date Title
EA201401134A1 (ru) Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
EA201200526A1 (ru) Поливалентные антитела, стабилизированные дисульфидом
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
CY1118713T1 (el) Βιολογικα προϊοντα
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
RU2016100892A (ru) Антитела против tweakr и их применение
WO2003106495A3 (en) MONOCLONAL ANTIBODY HPAM4
MX2009008143A (es) Antienos multivariables acomplejados con anticuerpo monoclonal humanizado de apuntamiento.
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
SI2424569T1 (en) Immunoconjugated anti-mesothelin and their use
RS52860B (en) ANTI-ILT7 ANTITELO
CR20110577A (es) Proteínas de unión a il-1
IN2014MN00873A (ru)
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses